Mon panier

Human CD9 Full Length Protein, Flag,His Tag (Detergent)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
CD9-H52D3-20ug
$805.00
CD9-H52D3-100ug
$2985.00
CD9-H52D3-500ug
$7480.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Application

    1. Immunization
    2. Affinity testing (SPR / BLI)
    3. Screening (ELISA)
  • Synonyms

    CD9, MIC3, TSPAN29, GIG2, MRP1, BTCC1, DRAP27, 5H9

  • Source

    Detergent Human CD9 Full Length Protein, Flag,His Tag (CD9-H52D3) is expressed from human 293 cells (HEK293). It contains AA Pro 2 - Val 228 (Accession # NP_001760.1).

    Predicted N-terminus: Met

    Request for sequence
  • Molecular Characterization

    CD9 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a flag tag at the N-terminus and a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 28.6 kDa.

    *The DDM/CHS buffer (Cat. No. DC-11) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Each full-length transmembrane protein is encapsulated by detergent micelle.

    2. Synthesis Process

      Through mild detergent micelle extraction, dedicated solubilization, and stringent affinity purification, we maximally retain the native transmembrane conformation of full-length transmembrane proteins throughout downstream purification. This workflow yields purified, detergent-solubilized proteins free of unrelated membrane impurities and exogenous scaffold proteins, with exceptional purity, accurate quantitation, and well-preserved biological activity—ideal for immunization, binding assays in antibody discovery and screening (ELISA) and affinity testing (SPR and BLI), etc.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    This product is not suitable for cell based experiments due to cytotoxicity of DDM.
    DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumstances should you remove DDM and CHS.
    DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
    If glycerol is not compatible with your application, remove glycerol just before the immediate experiment, and NEVER store glycerol-free protein solution.

    Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Bioactivity-ELISA

     CD9 ELISA

    Immobilized Human CD9 Full Length Protein, Flag,His Tag (Cat. No. CD9-H52D3) at 1 μg/mL (100 μL/well) can bind Anti-CD9 Antibody with a linear range of 0.005-0.313 μg/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     CD9 SPR

    Monoclonal Anti-CD9 Antibody, Human IgG1 captured on Protein A Chip can bind Human CD9 Full Length Protein, Flag,His Tag (Cat. No. CD9-H52D3) with an affinity constant of 75.5 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

A tetraspanin broadly expressed on immune cells, platelets, and exosomes. It regulates cell fusion, sperm-egg fusion, and tumor cell motility. CD9 is a canonical exosome marker. In oncology, CD9 can function as either a metastasis suppressor or promoter depending on the cellular context and integrin associations.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    CD9 antigen

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    1 Détails

  • Étape de développement la plus élevée:

    Phase 1 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte